Effectively Treating Community-Associated MRSA Infections
June 18, 2008
12:00-1:30pm Eastern Daylight Time
1.5 contact hours*
Pharmacy Continuing Education Approved (ACPE #: 207-999-08-045-L04-P )
Nursing Continuing Education Approved (VNA#: 05-08-082) (Expires April 30, 2010)
MRSA-related cases have been steadily making headlines across the country—pushing it into mainstream dialogue. What do you need to know as an alternate-site infusion professional? Find out from an authority on MRSA—Dr. Seth David Rosenbaum!
Program Description:
Methicillin-resistant Staph Aureus (MRSA) has emerged in the community with clinical, epidemiologic and bacteriologic characteristics distinct from healthcare associated MRSA. Community-Associated MRSA (CA-MRSA) infections are fast becoming common in the general population, requiring a change in therapeutic approach. Gather with colleagues to acquire the vital information essential for clinicians to have when making appropriate recommendations for the most effective therapy.
Dr. Rosenbaum was an expert speaker on this topic to over 200+ breakfast symposium attendees during the 2008 NHIA Annual Conference. Ideal for all alternate-site infusion clinicians, Dr. Rosenbaum will share his coveted knowledge through this highly-anticipated audio conference. Register early and gain first-hand information from this industry leader and pioneer. Remember, these audios make great training sessions—as one phone line can train unlimited number of people (see below for additional requirements for those seeking pharmacy or nursing continuing education)!*
Faculty:
Seth David Rosenbaum, MD Medical Specialty Associates, Infectious Diseases, Cherry Hill, NJ
Faculty Bio:
Dr. Rosenbaum is currently an attending physician for infectious diseases and internal medicine at Medical Specialty Associates, PA. Throughout his career, Dr. Rosenbaum has provided emergency medical service to a New Jersey township, acted as an officer on a volunteer EMS rescue squad, and assisted with the evaluation and instruction of senior medical students in OSCE program.
Dr. Rosenbaum has received many awards in his field and holds certifications from the American Board of Internal Medicine and the American Board of Internal Medicine—Infectious Diseases among many others.
Educational Objectives:
After completion of this program the learner will:
- Discuss the emergence of Community Associated Methicillin resistant Staph Aureus (CA-MRSA).
- Outline the factors leading to increasing rates of S. Aureus bacteremia.
- List five risk factors for CA-MRSA.
- Identify specific benefits of early appropriate therapy when treating CA-MRSA.
- List the current FDA approved agents for treating CA MRSA.
Continuing Education:
To apply for continuing education credit in nursing or pharmacy for this program, please do the following:
- Kindly complete the evaluation form and the Statement of Continuing Education Credit form for this audio conference. You will receive the link to these forms in an email 24-48 hours prior to the audio conference.
- Fax the evaluation and certificate forms to the attention of Eleanor Nespica at 703-683-1484.
- Your certificate for continuing education will be validated and faxed to you within three – four weeks of NHIA’s receipt of all completed forms.
- Please be aware that you are responsible for filing a copy of your certificate with your state board(s).
*Note: To receive Pharmacy Continuing Education credit, registered participants must individually sign-in to the call and attend the entire audio conference. Only paid registrants for this audio conference are eligible for Continuing Education credit. Parties who listen to the audio conference, but who have not paid, registered and called-in individually, cannot be granted Continuing Education. If you have any questions regarding Continuing Education Credit for this program, please contact Eleanor Nespica, Education Programs Manager, at the NHIA office: 703-549-3740 or eleanor.nespica@nhia.org
Target Audience:
Clinical and other professionals in the alternate-site infusion community.